ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1434

Neuropathic Pain in Patients with Rheumatoid Arthritis: Relation with Clinical Variables

Ferda Kaygisiz1, Pinar Borman2 and Aynur Karagoz3, 1Dept of Physical Medicine and Rehabilitation, Ankara Training and Research Hospital, Ankara, Turkey, 2Department of Physical Medicine and Rehabilitation, University of Hacettepe Faculty of Medicine, Ankara, Turkey, 3Dept of Physical Medicine and Rehabilitation, Ministry of Health, Ankara Training and Research Hospital, Ankara, Turkey

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Disability, neuropathy, pain, quality of life and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Pain: Basic and Clinical Aspects Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

There are few studies in the literature indicating that neuropathic pain occurs in rheumatoid arthritis (RA). The aim of this cross sectional study was to evaluate frequency of neuropathic hand pain in RA patients and to determine the relation with clinical variables and occurrence of neuropathic pain.

Methods:

A hundred-nineteen RA patients, who were not having any comorbid disease and/or using drugs that would cause neuropathy, were recruited to the study. Demographic properties (age, sex, disease duration) and clinical characteristics (pain by VAS, functional status, disease activity and quality of life (QoL) assessed by HAQ, DAS28 and RAQoL respectively) were recorded. The neuropathic property of hand pain was assessed by both Leeds assessment of neuropathic symptoms and signs pain scale (LANSS), Douleur Neuropathique4 (DN4) and Pain-DETECT scales. Descriptive statistics was used for clinical variables and frequency of neuropathic pain. The difference of clinical variables between patients with and without neuropathic pain, were examined using t tests and chi square tests for continuous and categorical variables respectively. Correlation coefficients of clinical variables and neuropathic pain scores were analyzed with Spearman correlation analyses.  The significance threshold was set as p values less than 0.05.

Results:

61 female, 58 male RA patients with a mean age of 50.51± 12.45 years, were included to the study. Neuropathic pain was detected in 76 (%63.9), 70 (%58.8), 61(%51.3) RA patients depending on the LANSS(scores>12), DN4(scores>4) and painDETECT(scores>12) questionnaires respectively. The mean levels of VAS-pain, HAQ and RAQoL scores were significantly higher in patients having neuropathic pain than in patients not having (p<0.05) (Table 1,2). The scores of the neuropathic pain scales were correlated with each other but not with the scores of disease activity.

Conclusion:

Neuropathic hand pain is determined in more than half of the patients with RA and related with pain intensity, functional status and QoL. Diagnosis and treatment of neuropathic pain are warranted in order to improve pain, disability and quality of life in RA patients.

Table-1. The clinical properties of patients having and lacking neuropathic pain, determined by LANSS.

 

Neuropathic pain (+)

n=76

Neuropathic pain (-)

n=43

p

VAS

5.93±2.23

4.44±2.54

0.001

DAS28-ESH

3.10±0.91

2.96±0.84

0.424

RAQoL

16.46±7.65

11.28±6.82

0.001

HAQ

1.38±0.74

0.91±0.73

0.001

 

Table-2. The clinical properties of patients having and lacking neuropathic pain, determined by DN4

 

Neuropathic pain (+)

n=70

Neuropathic pain (-)

n=49

p

VAS

5.77±2.47

4.85±2.33

0.049

DAS28-ESH

2.99±0.91

3.13±1.08

0.428

RAQoL

16.80±7.47

11.43±7.07

<0.001

HAQ

0.96±0.73

0.96±0.73

0.002


Disclosure: F. Kaygisiz, None; P. Borman, None; A. Karagoz, None.

To cite this abstract in AMA style:

Kaygisiz F, Borman P, Karagoz A. Neuropathic Pain in Patients with Rheumatoid Arthritis: Relation with Clinical Variables [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/neuropathic-pain-in-patients-with-rheumatoid-arthritis-relation-with-clinical-variables/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/neuropathic-pain-in-patients-with-rheumatoid-arthritis-relation-with-clinical-variables/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology